vericiguat
Term · Oncology and biomedicine · MLC-T-ONC-017494
An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity. Upon oral administration, vericiguat directly stimulates the catalytic activity of sGC and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to nitric oxide (NO) binding to heme. Vericiguat stimulates sGC independently of and synergistically with NO.
| Identifier | MLC-T-ONC-017494 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017494",
"term": "vericiguat",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity. Upon oral administration, vericiguat directly stimulates the catalytic activity of sGC and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to nitric oxide (NO) binding to heme. Vericiguat stimulates sGC independently of and synergistically with NO.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vericiguat/"
}
Record 17,202 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.